NeuroOne Medical Technologies Corporation Common Stock
NMTCNeuroOne Medical Technologies Corporation (NMTC) is a medical device company focused on developing and commercializing innovative neural interfaces and neurostimulation solutions. The company's technologies aim to improve diagnosis and treatment options for neurological disorders, such as epilepsy and chronic pain, by providing minimally invasive and precise neural interface solutions. Founded to advance neurotechnology, NeuroOne seeks to enhance patient outcomes through its specialized devices and ongoing research efforts.
Company News
NeuroOne Medical Technologies reported strong Q3 2025 performance with 105% product revenue growth, improved gross margins, and promising clinical milestones for its OneRF ablation system, including the first patient achieving 12-month seizure freedom.
NeuroOne Medical Technologies Corporation will release its fiscal first quarter 2025 financial results on February 12, 2025, and host an investor conference call to discuss the results and provide a corporate update.
NeuroOne Medical Technologies Corporation has been notified by Nasdaq that it is not in compliance with the minimum bid price requirement, and faces delisting if it fails to regain compliance within the grace period.
ICD-10-PCS code for first to market, FDA-cleared thin-film, sEEG-guided RF ablation system effective October 1, 2024
EDEN PRAIRIE, Minn., May 14, 2024 (GLOBE NEWSWIRE) -- NeuroOne Medical Technologies Corporation (NASDAQ: NMTC) (“NeuroOne” or the “Company”), a medical technology company focused on improving surgical care options and outcomes for patients suffering from neurological disorders, today announces its operating results for the second quarte...
